CCR5 and infection: Another study, NCT03617198, combined a CAR-T cell therapy with ZFN CCR5 modification in a form of dual therapy that ensured that the CD4+ cells are resistant to infection and, at the same time, capable of detecting and clearing HIV-infected cells.